Top Markets
Coin of the day
GeneOne Life Science, Inc. GeneOne Life Science, Inc.

GeneOne Life Science, Inc.

011000
Rankning i aktier #27572
GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul,... GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.
Aktiekurs
$1.85
Senast synkroniserad: 2026-07-27
Marknadsvärde
$32.07M
Förändring (1 dag)
0.00%
Förändring (1 år)
-76.96%
Land
KR
Handel GeneOne Life Science, Inc. (011000)

Kategori

P/B-tal för GeneOne Life Science, Inc. (011000)
P/B-tal per 2026 TTM: 0
Enligt GeneOne Life Science, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 0. I slutet av 2026 hade företaget ett P/B-tal på 0.
Historik för P/B-tal för GeneOne Life Science, Inc. från 2026 till 2026
P/B-tal vid årets slut
År P/B-tal Ändra
Inte tillräckligt med data för de angivna datumen.
P/B-tal för liknande företag eller konkurrenter
Företag P/B-tal Skillnad i P/B-tal Land
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH